These studies suggest that BMPR2 inhibition synergizes with cancer therapeutics by inducing high ROS levels, which amplifies the influx of calcium into the mitochondria, leading to mtROS and mtCa++ overload. This evidence concerns the gene BMPR2 and cancer.